OUI’s Vasculitis Scores

OUI’s Vasculitis focused Clinical Outcome Assessment suite, provides a comprehensive set of tools designed to assess disease activity, organ damage, and treatment impact in patients with systemic vasculitis. This portfolio includes:

Instrument	Overview	Assessment Domains
	The Birmingham Vasculitis Activity Score (BVAS) is a validated tool for assessment of disease activity in patients with many different forms of vasculitis.	The BVAS assess disease activity, flare, remission and the chronic effects of systemic vasculitis. The methods are practical and clinically based to enable standardized measurements of disease status, which consist of measuring: Current disease activity Recent disease activity that is not fully resolved
	The Vasculitis Damage Index (VDI) is the most widely used and validated method to document vasculitis damage irrespective of disease activity.	The VDI consists of a list of findings grouped into 11 systems: musculoskeletal; skin/mucous membranes; ocular; ENT; pulmonary; cardiovascular; peripheral vascular disease; gastrointestinal; renal; neuropsychiatric and an additional section for additional damage items. The “other” section includes gonadal failure, marrow failure, diabetes, chemical cystitis, malignancy, as well as the opportunity to document any other unlisted feature that can be considered as damage.
	The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV PRO) is a validated 29-item, disease-specific PRO measure for ANCA-associated vasculitis and used to assess the health-related quality of life and disease burden experienced by patients.	Questions are group together into 6 domains: Organ-Specific Symptoms Systemic Symptoms Treatment Side Effects Social and Emotional Impact Concerns about the Future Physical Function
	The Giant Cell Arteritis Patient Reported Outcome Measure (GCA-PRO) is a validated tool to measure symptoms and impact on health-related quality of life in patients with Giant Cell Arteritis. It can also be used as a communication tool between patients and their clinicians, to highlight areas of greatest importance to patients, within face to face or online consultations.	The GCA-PRO containings 30 items which are grouped into 4 domains or “super-items” that measure specific aspects of the impact of disease.  A total GCA PRO score can also be calculated. These domains are: Acute symptoms Activities of Daily Living Psychological Impact Participation
	The Steroid Patient Reported Outcome Measure (Steroid PRO) is the first validated and reliable patient-reported outcome measure designed to assess the impact of glucocorticoid-specific therapy on patients’ well-being and quality of life.	Domains reflect the severity, frequency, or impact of symptoms, side effects, or other aspects of steroid therapy on the patient’s well-being.

These tools provide clinicians with critical metrics to evaluate disease progression, treatment efficacy, and patient well-being, facilitating informed treatment decisions and personalized care strategies to enhance long-term outcomes.

You can find out more by clicking through to the PROfile pages via the links above or by getting in touch with the clinical outcomes team at healthoutcomes@innovation.ox.ac.uk.